FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2260342629> ?p ?o ?g. }

• W2260342629 endingPage "1207" @default.
• W2260342629 startingPage "1197" @default.
• W2260342629 abstract "Purpose An open-label, noninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in patients receiving chemotherapy for metastatic breast cancer. Methods Women with hemoglobin ≤ 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer, were randomly assigned to EPO 40,000 IU subcutaneously once a week or best standard of care. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, time to tumor progression, overall response rate, RBC transfusions, and thrombotic vascular events. Results In 2,098 patients randomly assigned, median PFS (based on investigator-determined disease progression [PD]) was 7.4 months in both groups (hazard ratio [HR], 1.089; 95% CI, 0.988 to 1.200); upper bound exceeded prespecified noninferiority margin of 1.15. Median PFS per independent review committee–determined PD was 7.6 months in both groups (HR, 1.028; 95% CI, 0.922 to 1.146); upper bound did not exceed prespecified noninferiority margin. Median overall survival at clinical cutoff (1,337 deaths) was 17.2 months in the EPO and 17.4 months in the best standard of care group (HR, 1.057; 95% CI, 0.949 to 1.177), median time to tumor progression was 7.5 months in both groups (HR, 1.094; 95% CI, 0.991 to 1.209), and overall response rate was 50% versus 51% (odds ratio, 0.950; 95% CI, 0.799 to 1.130). RBC transfusions were 5.8% versus 11.4% (P < .001), and thrombotic vascular events were 2.8% versus 1.4% (P = .038), respectively. Conclusion The primary end point, PFS based on investigator-determined PD, did not meet noninferiority criteria. As a consistency assessment with the primary finding, PFS based on independent review committee–determined PD met noninferiority criteria. Overall, this study did not achieve noninferiority objective in ruling out a 15% increased risk in PD/death. RBC transfusion should be the preferred approach for the management of anemia in this population." @default.
• W2260342629 created "2016-06-24" @default.
• W2260342629 creator A5012270583 @default.
• W2260342629 creator A5015317835 @default.
• W2260342629 creator A5019547742 @default.
• W2260342629 creator A5020747611 @default.
• W2260342629 creator A5022395037 @default.
• W2260342629 creator A5030601070 @default.
• W2260342629 creator A5037423477 @default.
• W2260342629 creator A5037759627 @default.
• W2260342629 creator A5038092151 @default.
• W2260342629 creator A5046445349 @default.
• W2260342629 creator A5054753125 @default.
• W2260342629 creator A5064206524 @default.
• W2260342629 creator A5066442784 @default.
• W2260342629 creator A5066657357 @default.
• W2260342629 creator A5067130416 @default.
• W2260342629 creator A5067362504 @default.
• W2260342629 creator A5067479903 @default.
• W2260342629 creator A5067861811 @default.
• W2260342629 creator A5068271757 @default.
• W2260342629 creator A5068874945 @default.
• W2260342629 creator A5069760978 @default.
• W2260342629 creator A5074106791 @default.
• W2260342629 creator A5085789507 @default.
• W2260342629 date "2016-04-10" @default.
• W2260342629 modified "2023-10-01" @default.
• W2260342629 title "A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy" @default.
• W2260342629 cites W1821554592 @default.
• W2260342629 cites W1867073577 @default.
• W2260342629 cites W1884165293 @default.
• W2260342629 cites W1885881044 @default.
• W2260342629 cites W2001453738 @default.
• W2260342629 cites W2002189627 @default.
• W2260342629 cites W2004502886 @default.
• W2260342629 cites W2019799425 @default.
• W2260342629 cites W2020710243 @default.
• W2260342629 cites W2024159843 @default.
• W2260342629 cites W2024257379 @default.
• W2260342629 cites W2033281335 @default.
• W2260342629 cites W2060276223 @default.
• W2260342629 cites W2069264184 @default.
• W2260342629 cites W2077995274 @default.
• W2260342629 cites W2088369648 @default.
• W2260342629 cites W2097225239 @default.
• W2260342629 cites W2101364791 @default.
• W2260342629 cites W2128950429 @default.
• W2260342629 cites W2129841021 @default.
• W2260342629 cites W2132904074 @default.
• W2260342629 cites W2139248078 @default.
• W2260342629 cites W2145869599 @default.
• W2260342629 cites W2150250025 @default.
• W2260342629 cites W2152016993 @default.
• W2260342629 cites W2158158444 @default.
• W2260342629 cites W2164837040 @default.
• W2260342629 cites W2169372049 @default.
• W2260342629 cites W2171137595 @default.
• W2260342629 cites W3147151963 @default.
• W2260342629 doi "https://doi.org/10.1200/jco.2015.63.5649" @default.
• W2260342629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26858335" @default.
• W2260342629 hasPublicationYear "2016" @default.
• W2260342629 type Work @default.
• W2260342629 sameAs 2260342629 @default.
• W2260342629 citedByCount "50" @default.
• W2260342629 countsByYear W22603426292016 @default.
• W2260342629 countsByYear W22603426292017 @default.
• W2260342629 countsByYear W22603426292018 @default.
• W2260342629 countsByYear W22603426292019 @default.
• W2260342629 countsByYear W22603426292020 @default.
• W2260342629 countsByYear W22603426292021 @default.
• W2260342629 countsByYear W22603426292022 @default.
• W2260342629 countsByYear W22603426292023 @default.
• W2260342629 crossrefType "journal-article" @default.
• W2260342629 hasAuthorship W2260342629A5012270583 @default.
• W2260342629 hasAuthorship W2260342629A5015317835 @default.
• W2260342629 hasAuthorship W2260342629A5019547742 @default.
• W2260342629 hasAuthorship W2260342629A5020747611 @default.
• W2260342629 hasAuthorship W2260342629A5022395037 @default.
• W2260342629 hasAuthorship W2260342629A5030601070 @default.
• W2260342629 hasAuthorship W2260342629A5037423477 @default.
• W2260342629 hasAuthorship W2260342629A5037759627 @default.
• W2260342629 hasAuthorship W2260342629A5038092151 @default.
• W2260342629 hasAuthorship W2260342629A5046445349 @default.
• W2260342629 hasAuthorship W2260342629A5054753125 @default.
• W2260342629 hasAuthorship W2260342629A5064206524 @default.
• W2260342629 hasAuthorship W2260342629A5066442784 @default.
• W2260342629 hasAuthorship W2260342629A5066657357 @default.
• W2260342629 hasAuthorship W2260342629A5067130416 @default.
• W2260342629 hasAuthorship W2260342629A5067362504 @default.
• W2260342629 hasAuthorship W2260342629A5067479903 @default.
• W2260342629 hasAuthorship W2260342629A5067861811 @default.
• W2260342629 hasAuthorship W2260342629A5068271757 @default.
• W2260342629 hasAuthorship W2260342629A5068874945 @default.
• W2260342629 hasAuthorship W2260342629A5069760978 @default.
• W2260342629 hasAuthorship W2260342629A5074106791 @default.
• W2260342629 hasAuthorship W2260342629A5085789507 @default.
• W2260342629 hasConcept C121608353 @default.
• W2260342629 hasConcept C126322002 @default.

• next